RGNX: Late-stage gene therapy programs show strong efficacy, with pivotal data and regulatory filings imminent
The company is advancing late-stage gene therapy programs in DMD and ophthalmology, with RGX-202 showing strong efficacy and safety data and a BLA submission planned for early next year. Large pivotal trials in wet AMD are nearing top-line data, and financial resources are expected to last into lat…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.